Mega Lifesciences Management

Management criteria checks 2/4

Mega Lifesciences' CEO is Vivek Dhawan, appointed in Jan 1988, has a tenure of 37.33 years. directly owns 6.59% of the company’s shares, worth THB1.68B. The average tenure of the management team and the board of directors is 27.3 years and 12.3 years respectively.

Key information

Vivek Dhawan

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	37.3yrs
CEO ownership	6.6%
Management average tenure	27.3yrs
Board average tenure	12.3yrs

Recent management updates

Recent updates

CEO

Vivek Dhawan (63 yo)

37.3yrs

Tenure

Mr. Vivek Dhawan is CEO & Executive Director of Mega Lifesciences Public Company Limited from 2013. He joined the Mega Lifesciences Public Company Limited in 1986. He is CEO & Chief Coach of Mega Lifescien...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vivek Dhawan	CEO & Executive Director	37.3yrs	no data	6.59% THB 1.7b
Thomas Abraham	CFO & Executive Director	27.3yrs	no data	0.76% THB 195.0m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	no data	no data
Paramjit Sawhney	President of International	no data	no data	1.5% THB 382.7m
Girish Wadhwa	President of Myanmar	no data	no data	no data
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	no data	1.48% THB 376.8m
Sujintana Boonworapat	Corporate Secretary	no data	no data	0.019% THB 5.0m
Manoj Gurbuxani	Deputy Chief Financial Officer	5.3yrs	no data	0.000010% THB 2.6k

27.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: MEGA's management team is seasoned and experienced (27.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Vivek Dhawan	CEO & Executive Director	12.3yrs	no data	6.59% THB 1.7b
Thomas Abraham	CFO & Executive Director	27.3yrs	no data	0.76% THB 195.0m
Yim Chi	Independent Vice Chairman	12.3yrs	฿1.65m	no data
Kirit Chimanlal Shah	Non-Executive Director	12.3yrs	฿694.58k	49.81% THB 12.7b
Shiraz Poonevala	Non-Executive Director	12.3yrs	฿694.58k	no data
Ishaan Shah	Non-Executive Director	12.3yrs	฿694.58k	0.32% THB 81.5m
Mechai Viravaidya	Independent Chairman	12.3yrs	฿2.32m	no data
Sameera Shah	Non-Executive Director	12.3yrs	฿694.58k	no data
Thor Santhisiri	Independent Director	12.3yrs	฿1.20m	0.022% THB 5.6m
Vijay Karwal	Independent Director	4yrs	฿1.20m	no data
Nithinart Sinthudeacha	Independent Director	2.1yrs	฿1.20m	no data

12.3yrs

Average Tenure

61yo

Average Age

Experienced Board: MEGA's board of directors are seasoned and experienced ( 12.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/03 04:05
End of Day Share Price	2025/05/02 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mega Lifesciences Public Company Limited is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yuwanee Prommaporn	BNP Paribas Securities (Asia)
Graham Price	CGS International
Chanpen Sirithanarattanakul	DBS Bank Ltd

Mega Lifesciences Management

Management criteria checks 2/4

Key information

Recent management updates

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 04, 2025

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

Mega Lifesciences Public Company Limited to Report Q1, 2025 Results on May 14, 2025

Price target decreased by 9.7% to ฿34.57

Now 20% undervalued after recent price drop

Final dividend of ฿0.80 announced

Full year 2024 earnings: EPS and revenues miss analyst expectations

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 04, 2025

Price target decreased by 7.3% to ฿42.57

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age